{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:01:47Z","timestamp":1789790507676,"version":"4.0.1"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0526200"],"award-info":[{"award-number":["2024ZD0526200"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.drup.2026.101468","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:36:49Z","timestamp":1786549009000},"page":"101468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consensus on standardized later-line systemic therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"89","author":[{"given":"Hongli","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-8200","authenticated-orcid":false,"given":"Jung Weon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayarsaikhan","family":"Enkhjargal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-990X","authenticated-orcid":false,"given":"Teiji","family":"Kuzuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Oura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Shiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101468_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.drup.2026.101468_bib2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2026.101468_bib3","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2767-9764.CRC-23-0072","article-title":"Salvage ipilimumab plus nivolumab after anti-PD-1\/PD-L1 therapy in advanced hepatocellular carcinoma","volume":"3","author":"Alden","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.drup.2026.101468_bib4","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses\u2026","volume":"41","author":"Allaire","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.drup.2026.101468_bib5","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/cam4.5123","article-title":"Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"12","author":"Bang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101468_bib6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221097934","article-title":"Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis","volume":"14","author":"Bang","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drup.2026.101468_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","article-title":"Insights into the success and failure of systemic therapy for hepatocellular carcinoma","volume":"16","author":"Bruix","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.drup.2026.101468_bib11","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.jhep.2024.01.007","article-title":"Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma","volume":"80","author":"Chan","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","article-title":"Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment","volume":"81","author":"Chan","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib13","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.3390\/cancers13184584","article-title":"Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib14","article-title":"Efficacy and safety of regorafenib and PD-1 combined with cryoablation in the treatment of advanced hepatocellular carcinoma after second-line targeted therapy","volume":"41","author":"Chen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib15","doi-asserted-by":"crossref","DOI":"10.1159\/000551629","article-title":"Immune checkpoint inhibitor rechallenge in unresectable hepatocellular carcinoma: a multicenter efficacy and safety study","author":"Chen","year":"2026","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib16","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2147\/DDDT.S386829","article-title":"Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study","volume":"16","author":"Chen","year":"2022","journal-title":"Drug. Des. Devel Ther."},{"key":"10.1016\/j.drup.2026.101468_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000543666","article-title":"Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab","volume":"14","author":"Cheon","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib18","article-title":"Transjugular retrograde obliteration prior to liver resection for hepatocellular carcinoma associated with hyperammonemia due to spontaneous portosystemic shunt","volume":"2013","author":"Chikamori","year":"2013","journal-title":"Case Rep. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib19","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3390\/cancers12071968","article-title":"Effectiveness and safety of nivolumab in Child\u2013Pugh b patients with hepatocellular carcinoma: a real-world cohort study","volume":"12","author":"Choi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3350\/cmh.2023.0553","article-title":"Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: A real-world study","volume":"30","author":"Chon","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib21","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/cancers16071388","article-title":"Management of portal hypertension in patients with hepatocellular carcinoma on systemic treatment: current evidence and future perspectives","volume":"16","author":"De Gaetano","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00270-020-02444-2","article-title":"The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT","volume":"43","author":"De la Torre-Al\u00e1ez","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"10.1016\/j.drup.2026.101468_bib23","first-page":"581","article-title":"Guideline for diagnosis and treatment of primary liver cancer (2024 version)","volume":"32","author":"Department of Medical Administration NHCotPsRoC","year":"2024","journal-title":"Chin. J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib24","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.62347\/IIHG2242","article-title":"Efficacy and safety analysis of PD-1 combined with regorafenib in the treatment of advanced hepatocellular carcinoma","volume":"16","author":"Dong","year":"2024","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.drup.2026.101468_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11864-024-01246-9","article-title":"The trend of the treatment of advanced hepatocellular carcinoma: Combination of immunotherapy and targeted therapy","volume":"25","author":"Dong","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231189425","article-title":"Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting","volume":"15","author":"Falette-Puisieux","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib27","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.3390\/cancers14246245","article-title":"Resistance to antiangiogenic therapy in hepatocellular carcinoma: from molecular mechanisms to clinical impact","volume":"14","author":"Federico","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000515490","article-title":"Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-life cohort","volume":"10","author":"Finkelmeier","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib29","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101468_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib31","doi-asserted-by":"crossref","first-page":"LBA4008","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.598877","article-title":"Augmenting anticancer immunity through combined targeting of angiogenic and PD-1\/PD-L1 pathways: challenges and opportunities","volume":"11","author":"Hack","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101468_bib33","first-page":"1022","article-title":"Tumor Evaluation Criteria in Hepatocyte Immune\/Targeted Therapy: A Comparative Study","volume":"29","author":"Han","year":"2021","journal-title":"Chin. J. Med. Imaging"},{"key":"10.1016\/j.drup.2026.101468_bib34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.17998\/jlc.2024.08.13","article-title":"Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study","volume":"24","author":"Han","year":"2024","journal-title":"J. Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib35","doi-asserted-by":"crossref","first-page":"21680","DOI":"10.1002\/cam4.6726","article-title":"Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach","volume":"12","author":"Hatanaka","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101468_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/hepr.13531","article-title":"Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study","volume":"50","author":"Hidaka","year":"2020","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drup.2026.101468_bib37","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/hepr.13644","article-title":"Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression","volume":"51","author":"Hiraoka","year":"2021","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drup.2026.101468_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/gastro\/goaa042","article-title":"Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma","volume":"9","author":"Hiraoka","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.drup.2026.101468_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.917384","article-title":"Real-life experience of regorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101468_bib40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000350841","article-title":"Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study","volume":"85","author":"Hsu","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.drup.2026.101468_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/JHC.S353956","article-title":"Regorafenib Combined with PD-1 blockade immunotherapy versus regorafenib as second-line treatment for advanced hepatocellular carcinoma: a multicenter retrospective study","volume":"9","author":"Huang","year":"2022","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.drup.2026.101468_bib42","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Iavarone","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.drup.2026.101468_bib43","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/lt.26264","article-title":"Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study","volume":"27","author":"Iavarone","year":"2021","journal-title":"Liver Transpl."},{"key":"10.1016\/j.drup.2026.101468_bib44","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jjco\/hyae048","article-title":"Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22","volume":"54","author":"Imaoka","year":"2024","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib45","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell."},{"key":"10.1016\/j.drup.2026.101468_bib46","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101468_bib47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/cld.929","article-title":"Cause for confusion: noncirrhotic hyperammonemic encephalopathy","volume":"15","author":"Kalra","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.drup.2026.101468_bib48","first-page":"1523","article-title":"Effect of systemic therapeutic drugs for hepatocellular carcinoma on portal hypertension","volume":"39","author":"Kang","year":"2023","journal-title":"J. Clin. Hepatolgy"},{"key":"10.1016\/j.drup.2026.101468_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e16114","article-title":"Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study","volume":"41","author":"Kaseb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000335963","article-title":"Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial","volume":"82","author":"Kaseb","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.drup.2026.101468_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/OTT.S91977","article-title":"Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma","volume":"9","author":"Kaseb","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101468_bib52","doi-asserted-by":"crossref","first-page":"S657","DOI":"10.1016\/j.annonc.2024.08.1006","article-title":"Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib53","doi-asserted-by":"crossref","first-page":"S1466","DOI":"10.1016\/j.annonc.2024.10.180","article-title":"Efficacy of ipilimumab plus nivolumab therapy in patients having hepatocellular carcinoma with main portal vein invasion (Vp4): Multicenter real-world study","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib54","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2025.43.4_suppl.551","article-title":"Nivolumab plus ipilimumab in advanced hepatocellular carcinoma with Child-Pugh B: A multicenter retrospective study","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2025.08.020","article-title":"Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab","volume":"84","author":"Kim","year":"2026","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/apt.15789","article-title":"Sequential systemic treatment in patients with hepatocellular carcinoma","volume":"52","author":"Kirstein","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.drup.2026.101468_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10637-024-01441-3","article-title":"Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)","volume":"42","author":"Kobayashi","year":"2024","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.drup.2026.101468_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000515552","article-title":"Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Koroki","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib61","doi-asserted-by":"crossref","first-page":"S1304","DOI":"10.1016\/j.annonc.2020.10.190","article-title":"IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC)","volume":"31","author":"Kudo","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib63","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.3390\/cancers15112952","article-title":"Clinical outcomes of cabozantinib in patients previously treated with atezolizumab\/bevacizumab for advanced hepatocellular carcinoma-importance of good liver function and good performance status","volume":"15","author":"Kuzuya","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib64","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","article-title":"Mechanisms of drug resistance in HCC","volume":"79","author":"Ladd","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.drup.2026.101468_bib65","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"18","author":"Lau","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.drup.2026.101468_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10637-020-00977-4","article-title":"Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea","volume":"39","author":"Lee","year":"2021","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.drup.2026.101468_bib68","first-page":"127","article-title":"Real-world study of systemic treatment after first-line atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries","volume":"14","author":"Lee","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1026337","article-title":"TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure","volume":"13","author":"Lei","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.drup.2026.101468_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241299678","article-title":"Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC","volume":"17","author":"Lei","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib71","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2024.12.039","article-title":"Maintaining first-line therapy plus radiation therapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma","volume":"122","author":"Leng","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.drup.2026.101468_bib72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/TCRM.S400079","article-title":"Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma","volume":"19","author":"Li","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.drup.2026.101468_bib73","doi-asserted-by":"crossref","DOI":"10.1159\/000549355","article-title":"Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review","author":"Li","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3892\/ol.2024.14451","article-title":"Regorafenib plus programmed death\u20111 inhibitors vs. regorafenib monotherapy in second\u2011line treatment for advanced hepatocellular carcinoma: A systematic review and meta\u2011analysis","volume":"28","author":"Li","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.drup.2026.101468_bib75","article-title":"Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101468_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1078155219846253","article-title":"Apatinib-induced hyperammonemic encephalopathy","volume":"26","author":"Liu","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.drup.2026.101468_bib78","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000536549","article-title":"Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma-with emphasis on locoregional therapy for oligoprogression","volume":"13","author":"Liu","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib79","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2147\/OTT.S383685","article-title":"Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice","volume":"15","author":"Liu","year":"2022","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.drup.2026.101468_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.livres.2024.05.001","article-title":"Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition)","volume":"8","author":"Liu","year":"2024","journal-title":"Liver Res."},{"key":"10.1016\/j.drup.2026.101468_bib81","first-page":"1031","article-title":"Treatment options after primary or secondary drug resistance to targeted immunotherapy in hepatocellular carcinoma","volume":"44","author":"Liu","year":"2024","journal-title":"ZHONGGUO SHIYONG WAIKE ZAZHI"},{"key":"10.1016\/j.drup.2026.101468_bib82","first-page":"465","article-title":"Analysis of potential resistance mechanism of liver cancer immunotherapy","volume":"28","author":"Lu","year":"2022","journal-title":"Chin. J. Hepatobiliary Surg."},{"key":"10.1016\/j.drup.2026.101468_bib83","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1186\/s12885-024-12780-y","article-title":"Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib85","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1186\/s12885-019-5989-2","article-title":"Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study","volume":"19","author":"Miksad","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.70131","article-title":"Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma","author":"Miura","year":"2026","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drup.2026.101468_bib87","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000515280","article-title":"Clinical outcomes of 2nd-and 3rd-Line regorafenib for advanced hepatocellular carcinoma","volume":"99","author":"Naruto","year":"2021","journal-title":"Oncology"},{"key":"10.1016\/j.drup.2026.101468_bib88","first-page":"1620","article-title":"Efficacy and safety of tyrosine kinase inhibitor combined with immune checkpoint inhibitor as the second-line therapy for advanced hepatocellular carcinoma","volume":"40","author":"Nie","year":"2024","journal-title":"J. Clin. Hepatolgy"},{"key":"10.1016\/j.drup.2026.101468_bib89","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.3390\/cancers16223880","article-title":"Sequential use of sorafenib and regorafenib in hepatocellular cancer recurrence after liver transplantation: Treatment strategies and outcomes","volume":"16","author":"Ozbay","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib90","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/07853890.2014.891355","article-title":"Assessment of response to therapy in hepatocellular carcinoma","volume":"46","author":"Patel","year":"2014","journal-title":"Ann. Med."},{"key":"10.1016\/j.drup.2026.101468_bib91","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.3390\/cancers13194882","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"13","author":"Pelizzaro","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib92","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3390\/cancers16162813","article-title":"Efficacy and safety of sorafenib or lenvatinib for advanced hepatocellular carcinoma after failure of first-line atezolizumab plus bevacizumab: A systematic review and meta-analysis","volume":"16","author":"Peng","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.05.021","article-title":"Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients","volume":"189","author":"Persano","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib94","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.1016\/j.annonc.2023.09.2138","article-title":"Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)","volume":"34","author":"Pinter","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib95","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ueg2.12626","article-title":"Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma","volume":"12","author":"Pomej","year":"2024","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1016\/j.drup.2026.101468_bib96","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/cancers12102961","article-title":"Vascular complications in patients with hepatocellular carcinoma treated with sorafenib","volume":"12","author":"Pomej","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7236","article-title":"Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study","volume":"13","author":"Qiao","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101468_bib98","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101468_bib99","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib100","first-page":"749","article-title":"Expert Consensus on the Clinical Application of Dronafibron in the Treatment of Hepatocellular Carcinoma","volume":"27","author":"Qin","year":"2022","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2021.0217","article-title":"The management of post-transplantation recurrence of hepatocellular carcinoma","volume":"28","author":"Rajendran","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib102","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.21037\/jgo-22-397","article-title":"Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China","volume":"13","author":"Ren","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib104","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib105","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jhep.2021.07.037","article-title":"Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma","volume":"75","author":"Ricke","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib106","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","article-title":"Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study","volume":"149","author":"Roessler","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib107","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/cancers16112042","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma and their hepatic-related side effects: a review","volume":"16","author":"Ruli","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib108","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/imt-2017-0180","article-title":"Is it possible to rechallenge with PD-1\/PD-L1 inhibitors after progression?","volume":"10","author":"Saleh","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.drup.2026.101468_bib109","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101468_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21528-2","article-title":"Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma","volume":"12","author":"Shimose","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101468_bib112","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/hepr.13852","article-title":"Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data","volume":"53","author":"Shimose","year":"2023","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drup.2026.101468_bib113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ueg2.12193","article-title":"Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters","volume":"10","author":"Sidali","year":"2022","journal-title":"U. Eur. Gastroenterol. J."},{"key":"10.1016\/j.drup.2026.101468_bib114","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3390\/biomedicines10102481","article-title":"Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy","volume":"10","author":"Sindhu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drup.2026.101468_bib115","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib116","first-page":"590","article-title":"Risk of bleeding in hepatocellular carcinoma patients treated with atezolizumab\/bevacizumab: a systematic review and meta-analysis","volume":"13","author":"Song","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib117","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/JHC.S519770","article-title":"Effectiveness and safety of systemic therapy and stereotactic body radiotherapy in oligoprogressive and oligometastatic hepatocellular carcinoma","volume":"12","author":"Song","year":"2025","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.drup.2026.101468_bib118","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.21037\/jgo-22-1170","article-title":"Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study","volume":"13","author":"Su","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib119","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3350\/cmh.2021.0308","article-title":"Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma","volume":"28","author":"Sung","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: Global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib121","first-page":"2702","article-title":"Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma","volume":"13","author":"Teng","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.drup.2026.101468_bib122","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/cancers17020278","article-title":"Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma previously treated with lenvatinib","volume":"17","author":"Terashima","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib123","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000515551","article-title":"Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma","volume":"10","author":"Tovoli","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib124","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/hepr.14130","article-title":"Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution study","volume":"55","author":"Uchikawa","year":"2025","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.drup.2026.101468_bib125","doi-asserted-by":"crossref","first-page":"36220","DOI":"10.18632\/oncotarget.26333","article-title":"The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension","volume":"9","author":"Uschner","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2026.101468_bib126","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2026.44.16_suppl.4002","article-title":"IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA\/mHCC) previously treated with atezo and bevacizumab (bev)","volume":"44","author":"Vogel","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib127","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41598-025-85831-4","article-title":"A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drup.2026.101468_bib128","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.21037\/jgo-22-626","volume":"13","author":"Wang","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104522","article-title":"Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials","volume":"204","author":"Wang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2026.101468_bib130","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.annonc.2023.09.2104","article-title":"Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study","volume":"34","author":"Wang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib131","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251334538","article-title":"Efficacy and safety of radiotherapy to delay second-line systemic therapy in patients with oligoprogressive hepatocellular carcinoma: study protocol of a multicentre, single-arm, phase II trial","volume":"17","author":"Wang","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib132","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2022.02.019","article-title":"PKC\u03b1\/ZFP64\/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma","volume":"77","author":"Wei","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib133","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001945","article-title":"Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors","volume":"9","author":"Wong","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib134","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10637-022-01248-0","article-title":"Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience","volume":"40","author":"Wu","year":"2022","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.drup.2026.101468_bib135","article-title":"Regorafenib second-line therapy for surgical recurrent hepatocellular carcinoma: An exploration of continuing regorafenib therapy after tumor progression\u2014A single-center retrospective analysis of 90 cases","volume":"41","author":"Wu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib136","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/MEG.0000000000002879","article-title":"Risk factors of complications after thermal ablation for hepatocellular carcinoma: the role of assessment of liver background","volume":"37","author":"Xie","year":"2025","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drup.2026.101468_bib137","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/s00330-023-10222-0","article-title":"Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST","volume":"34","author":"Xu","year":"2024","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.drup.2026.101468_bib138","article-title":"The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101468_bib139","first-page":"1","article-title":"A real-world drug safety surveillance study of lenvatinib from the FAERS database","author":"Yang","year":"2024","journal-title":"Expert. Opin. Drug. Saf."},{"key":"10.1016\/j.drup.2026.101468_bib140","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-025-14092-1","article-title":"Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib141","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers14122975","article-title":"Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study","volume":"14","author":"Yasui","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101468_bib142","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101468_bib143","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib144","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000525582","article-title":"Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: expert recommendations from Hong Kong, Singapore, and Taiwan","volume":"11","author":"Yau","year":"2022","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib145","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial","volume":"41","author":"Yau","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70711","article-title":"Mono-TKI and TKI plus ICI in unresectable hepatocellular carcinoma progression on first-line treatment of lenvatinib: A real-world study","volume":"14","author":"Yin","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.drup.2026.101468_bib147","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/liv.14496","article-title":"Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events","volume":"40","author":"Yoo","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.drup.2026.101468_bib148","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study","volume":"10","author":"Yoo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.drup.2026.101468_bib149","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-052294","article-title":"RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2022","journal-title":"BMJ Open."},{"key":"10.1016\/j.drup.2026.101468_bib150","first-page":"41","article-title":"Application of bevacizumab for malignant brain edema","volume":"44","author":"Yu","year":"2017","journal-title":"J. Int. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib151","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jjco\/hyy153","article-title":"Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma","volume":"49","author":"Yukimoto","year":"2019","journal-title":"Jpn J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib152","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.21037\/jgo-22-404","article-title":"Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study","volume":"13","author":"Zhai","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib153","article-title":"Efficacy and safety of regorafenib combined with PD-1 inhibitors in patients with advanced hepatocellular beyond atezolizumab plus bevacizumab: A retrospective analysis of real-world evidence","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib154","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2147\/JHC.S476439","article-title":"Impact of type of lenvatinib resistance on prognosis and second-line regimen in patients with virus-associated HCC","volume":"11","author":"Zhang","year":"2024","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.drup.2026.101468_bib155","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.21037\/jgo-23-590","article-title":"Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study","volume":"14","author":"Zhao","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/JHC.S512302","article-title":"Efficacy and safety of ipilimumab plus anti-PD-1\/PD-L1 antibodies combination therapy in advanced hepatocellular carcinoma patients progressing after multiple lines of treatment: a retrospective multicenter study","volume":"12","author":"Zheng","year":"2025","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.drup.2026.101468_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.764189","article-title":"Response evaluation and survival prediction following PD-1 inhibitor in patients with advanced hepatocellular carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST criteria","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.drup.2026.101468_bib158","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","article-title":"A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101468_bib159","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/JHC.S399874","article-title":"Efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma after sorafenib resistance","volume":"10","author":"Zou","year":"2023","journal-title":"J. Hepatocell. Carcinoma"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626001196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:07:46Z","timestamp":1789787266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626001196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":159,"alternative-id":["S1368764626001196"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101468","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on standardized later-line systemic therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101468"}}